What is the official website of Novartis México ?

The official website of Novartis México is www.novartis.com/mx-es.

What is Novartis México's cybersecurity risk score?

Novartis México has an AI-generated cybersecurity risk score of 759 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis México experienced?

According to Rankiteo, Novartis México currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis México been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis México has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis México have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis México is not certified under SOC 2 Type 1.

Does Novartis México have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis México does not hold a SOC 2 Type 2 certification.

Does Novartis México comply with GDPR ?

According to Rankiteo, Novartis México is not listed as GDPR compliant.

Does Novartis México have PCI DSS certification ?

According to Rankiteo, Novartis México does not currently maintain PCI DSS compliance.

Does Novartis México comply with HIPAA ?

According to Rankiteo, Novartis México is not compliant with HIPAA regulations.

Does Novartis México have ISO 27001 certification ?

According to Rankiteo,Novartis México is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis México operate in ?

Novartis México operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis México have ?

Novartis México employs approximately 607 people worldwide.

Does Novartis México own any subsidiaries ?

Novartis México presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis México have ?

Novartis México's official LinkedIn profile has approximately 96,715 followers.

What is the NAICS classification code for Novartis México ?

Novartis México is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis México have a Crunchbase profile ?

No, Novartis México does not have a profile on Crunchbase.

Does Novartis México have a LinkedIn profile ?

Yes, Novartis México maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartismexico.

How many cybersecurity incidents has Novartis México experienced ?

As of October 6, 2026, Rankiteo reports that Novartis México has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis México have ?

Novartis México has an estimated 5,774 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis México faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Cyber Attack and Breach.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis México

Boost Score +25 with badge (5 left)

759

/1000

Fair

784

/1000

Fair

Novartis México Vendor Cyber Rating & Cyber Score

novartis.com

Add Your Compliance Badge

Novartis Farmacéutica, S.A. de C.V. es individualmente “Responsable” de recabar sus datos personales, con domicilio en Av. Insurgentes Sur 2475, Tizapán San Ángel, Álvaro Obregón, 01090 Ciudad de México. Los datos personales que usted nos proporcione serán utilizados para cumplimentar la legislación respectiva. Para consultar nuestro Aviso de Privacidad Integral y los mecanismos para ejercer sus derechos, por favor visite www.novartis.com/mx-es Somos una compañía global con base en Suiza en la que buscamos descubrir nuevos caminos para prolongar y mejorar la vida de los pacientes en el mundo. Debes estar al tanto de los anuncios de trabajo falsos. En Novartis estamos consciente de las estafas recientes que hacen mal uso del nombre de

Novartis México

Novartis México CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis México

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis México Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis México

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis México in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis México in 2026.

Incident Types Novartis México vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis México in 2026.

Incident History - Novartis México (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis México Subsidiaries

Novartis México

Pharmaceutical Manufacturing

Website: www.novartis.com/mx-es

Company Size: 607

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis SlovakiaPharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis IsraelPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - NeurologieGeneesmiddelenproductie

Novartis Nederland - OncologieGeneesmiddelenproductie

Novartis Nederland - ReumatologieGeneesmiddelenproductie

Novartis Nederland - HematologieGeneesmiddelenproductie

Novartis Nederland - DermatologieGeneesmiddelenproductie

Novartis Nederland - Cardiovascular, Renal & Metabolism Geneesmiddelenproductie

Novartis NorgePharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Loading…

Novartis México Similar Companies

Novartis

novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, with 140 years of history, present in 140 countries worldwide, with a turnover of 4.88 billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants and is distributed across six continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Loading…

NEWS

Novartis México CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

January 25, 2026 08:00 AM

Novartis Renews WHO Commitment to Treat Leprosy by 2030

Novartis renewed its commitment with the WHO to treat 1 million more leprosy patients by 2030, extending a long-running global health...

Read Article

August 13, 2025 07:00 AM

Dräger’s Atlan A350 Series Gains US DoD Security Certification

Dräger's Atlan A350 anesthesia workstation series earns US DoD cybersecurity certification, securing patient data in operating rooms.

Read Article

February 22, 2021 08:00 AM

Treatment Access: Priority in Mexico

The Access to Medicine Foundation reveals that Mexico is among the countries with more strategies for therapies access.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-105761

SUMMARY

Dify is an open-source LLM app development platform. Prior to 1.16.0, the PUT /console/api/apps/<app_id>/server endpoint in api/controllers/console/app/mcp_server.py used AppMCPServerController.put() to retrieve an AppMCPServer by the client-supplied server ID without verifying that the server belonged to the requested application and tenant. An authenticated workspace member could therefore change another application's MCP server status and parameters, potentially redirecting data or disabling the service. This issue is fixed in version 1.16.0.

Published

Date2026-10-05

Updated

Date2026-10-05

RISK INFORMATION (Score: 7.1)

cvss3

Base Score: 7.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:H/A:L

Impact Score

4.2

Exploitability

2.8

REFERENCES

CVE-2026-105760

SUMMARY

vLLM is an inference and serving engine for large language models. Prior to 0.30.0, a caller can use the request-level media_io_kwargs field to select the GLMGA video backend and supply large values for the fps and max_frames options without a strict work ceiling. GLMGA constructs and deduplicates an attacker-sized pre-decode frame-index list, allowing a compact request and tiny valid video to consume disproportionate CPU time and memory in the shared media-loading executor. This issue is fixed in version 0.30.0.

Published

Date2026-10-05

Updated

Date2026-10-05

RISK INFORMATION (Score: 5.3)

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:L

Impact Score

1.4

Exploitability

3.9

REFERENCES

CVE-2026-105759

SUMMARY

vLLM is an inference and serving engine for large language models. Prior to 0.30.0, the Rust frontend's track_http_metrics middleware records the raw HTTP method token as a Prometheus label for requests reaching registered routes. An unauthenticated attacker can send unique arbitrary method tokens to unguarded routes such as /tokenize, causing Prometheus's Family::get_or_create function to permanently create counter and histogram label sets. Those label sets increase process memory usage and enlarge the /metrics response until the service or monitoring path is exhausted. This issue is fixed in version 0.30.0.

Published

Date2026-10-05

Updated

Date2026-10-05

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.2

REFERENCES

CVE-2026-105758

SUMMARY

vLLM is an inference and serving engine for large language models. From 0.24.0 until 0.30.0, the Qwen2VLVideoBackend and Qwen3VLVideoBackend classes accept request-level values for the media_io_kwargs.video.max_frames and media_io_kwargs.video.fps fields without enforcing server-side ceilings. An unauthenticated caller can submit these values to the /tokenize endpoint, causing the sampler to decode every frame selected from attacker-controlled video input, consume disproportionate frontend memory, and potentially terminate the API process before scheduling or admission control. The Rust frontend is not affected because it rejects the media_io_kwargs field. This issue is fixed in version 0.30.0.

Published

Date2026-10-05

Updated

Date2026-10-05

RISK INFORMATION (Score: 5.3)

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:L

Impact Score

1.4

Exploitability

3.9

REFERENCES

CVE-2026-105757

SUMMARY

vLLM is an inference and serving engine for large language models. Prior to 0.30.0, structured-output request failures can escape request-scoped validation and reach the EngineCore fatal-error path. A per-request backend mismatch can re-raise a grammar compilation exception, padding produced by the ngram_gpu speculative-decoding mode can pass a negative token to guidance validation, and the Rust frontend can admit empty structured-output values that the Python frontend rejects, allowing ordinary constrained-generation requests to terminate the shared engine. This issue is fixed in version 0.30.0.

Published

Date2026-10-05

Updated

Date2026-10-05

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Novartis México Vendor Cyber Rating & Cyber Score

Novartis México A.I CyberSecurity Scoring

Novartis México CyberSecurity News & History

Novartis México Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis México

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis México vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis México (X = Date, Y = Severity)

Novartis México Subsidiaries

Novartis México

Novartis México Similar Companies

Novartis

Sandoz

MACLEODS PHARMACEUTICALS LTD.

Intas Pharmaceuticals

MENARINI Group

Zoetis

Takeda

AbbVie

Glenmark Pharmaceuticals

Novartis México CyberSecurity News

Novartis Renews WHO Commitment to Treat Leprosy by 2030

Dräger’s Atlan A350 Series Gains US DoD Security Certification

Treatment Access: Priority in Mexico

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Novartis México CyberSecurity News & History

Novartis México Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis México

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis México vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis México (X = Date, Y = Severity)

Novartis México Subsidiaries

Novartis México

Novartis México Similar Companies

Novartis

Sandoz

MACLEODS PHARMACEUTICALS LTD.

Intas Pharmaceuticals

MENARINI Group

Zoetis

Takeda

AbbVie

Glenmark Pharmaceuticals

Novartis México CyberSecurity News

Novartis Renews WHO Commitment to Treat Leprosy by 2030

Dräger’s Atlan A350 Series Gains US DoD Security Certification

Treatment Access: Priority in Mexico

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo